Author:
Koerner John E.,Siegl Peter K. S.
Reference44 articles.
1. Ando K, Hombo T, Kanno A, Ikeda H, Imaizumi M, Shimizu N, Sakamoto K, Kitani S, Yamamoto Y, Hizume S, Nakai K, Kitayama T, Yamamoto K (2005) QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 99(5):487–500
2. Anon (1995) Japanese guidelines for non-clinical studies of drugs manual. Yakuji Nippo, Tokyo
3. Anon (1997) Committee for Proprietary Medicinal Products (EU). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products
4. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110(8):904–910
Bass A, Kinter L, Williams P (2004) Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 49:145–151
5. Cavero I (2009) Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin Drug Saf 8(6):627–47
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献